4D Molecular Therapeutics, Inc.
FDMT
4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial foā¦ read more
Healthcare
Biotechnology
5 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$8.68
Price-0.12%
-$0.01
1Y
Price
Market Cap
$405.378m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-61794.4%
EBITDA Margin-63195.6%
Net Profit Margin-51563.3%
Free Cash Flow MarginRevenue
$120k
+224.3%
1y CAGR+228.9%
3y CAGR+151.0%
5y CAGREarnings
-$209.177m
-30.0%
1y CAGR-27.8%
3y CAGR-33.5%
5y CAGREPS
-$3.75
-25.8%
1y CAGR-8.0%
3y CAGR-12.7%
5y CAGRBook Value
$368.983m
$423.982m
Assets$54.999m
Liabilities$22.263m
DebtDebt to Assets
5.3%
-0.1x
Debt to EBITDAFree Cash Flow
-$185.051m
-33.7%
1y CAGR-29.9%
3y CAGR-28.9%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company